bullish

Jiangxi Rimag IPO (2522.HK): Global Offering and Valuation Update

419 Views31 May 2024 18:44
I believe that Jiangxi Rimag is the best pure-play way to invest in a third-party medical imaging center market in Mainland China. The company is expected to price its IPO next week.
What is covered in the Full Insight:
  • IPO Terms
  • Global Offering
  • Use of Proceeds
  • Valuation Analysis
  • Conclusion
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top Quartile
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Information Technology & EnergyEquitiesEquity Capital MarketsThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x